跳至主要内容
临床试验/CTRI/2023/03/050334
CTRI/2023/03/050334招募中Unknown

Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.All children 2-18 years of age with CLD defined as presence of either of the following histological evidence of advanced fibrosis more than F2 on METAVIR staging or radiological imaging suggestive (heterogeneous hepatic echotexture, irregular nodular liver and/or caudate hypertrophy).
  • 2.Splenomegaly and/or platelets less than equals to 100.
  • 3.Coming for upper gastrointestinal endoscopy for variceal screening.
  • 4.Informed consent for HVPG and UGIE

排除标准

  • 1.Uncorrected heart defects (except small ASD)
  • 2.Cardiac conduction defects - arrythmias or heart block
  • 3.Interrupted inferior vena cava
  • 4.Situs inversus
  • 5.Patients who received beta-blockers in last 7 days
  • 6.Patients who received Octreotide infusion or bolus in last 7 days
  • 7.Variceal bleed in last 48 hours
  • 8.Shock or active sepsis
  • 9.Grade 2 /grade 3 ascites
  • 10.Severe hepatic impairment with MELD or PELD score >14
  • 11.Acute kidney injury (any grade)
  • 12.Hepatic encephalopathy (any grade)
  • 13.Known contraindications to propranolol in children:
  • 14.Hyper-reactive airway disease
  • 15.Hypertrophic cardiomyopathy
  • 16.Acute congestive heart failure

研究者

相似试验